MA43943A - Compositions et procédés pour traiter des patients avec des cellules mutantes rtk - Google Patents

Compositions et procédés pour traiter des patients avec des cellules mutantes rtk

Info

Publication number
MA43943A
MA43943A MA043943A MA43943A MA43943A MA 43943 A MA43943 A MA 43943A MA 043943 A MA043943 A MA 043943A MA 43943 A MA43943 A MA 43943A MA 43943 A MA43943 A MA 43943A
Authority
MA
Morocco
Prior art keywords
compositions
methods
treating patients
mutant cells
rtk
Prior art date
Application number
MA043943A
Other languages
English (en)
Inventor
Ge Wei
Original Assignee
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc filed Critical Ignyta Inc
Publication of MA43943A publication Critical patent/MA43943A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MA043943A 2015-05-29 2016-05-25 Compositions et procédés pour traiter des patients avec des cellules mutantes rtk MA43943A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562168237P 2015-05-29 2015-05-29
US201662309900P 2016-03-17 2016-03-17

Publications (1)

Publication Number Publication Date
MA43943A true MA43943A (fr) 2018-12-12

Family

ID=57441630

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043943A MA43943A (fr) 2015-05-29 2016-05-25 Compositions et procédés pour traiter des patients avec des cellules mutantes rtk

Country Status (8)

Country Link
US (2) US20180177792A1 (fr)
EP (1) EP3303382A4 (fr)
JP (2) JP6929231B2 (fr)
CN (1) CN107849113B (fr)
AU (1) AU2016270321B2 (fr)
CA (1) CA2987281A1 (fr)
MA (1) MA43943A (fr)
WO (1) WO2016196141A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033941A1 (fr) 2008-09-22 2010-03-25 Array Biopharma Inc. Composés imidazo[1,2b]pyridazine substitués comme inhibiteurs de kinases trk
MY169791A (en) 2008-10-22 2019-05-15 Array Biopharma Inc Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
ME03376B (fr) 2010-05-20 2020-01-20 Array Biopharma Inc Composés macrocycliques comme inhibiteurs de la kinase trk
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
CN113354649B (zh) 2014-11-16 2024-12-10 阵列生物制药公司 一种新的晶型
CN107207471B (zh) 2014-12-02 2020-06-26 伊尼塔公司 用于治疗神经母细胞瘤的组合
EP3368039A1 (fr) * 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Mutations ponctuelles dans le cancer résistant aux inhibiteurs de trk et méthodes associées
AU2016370846B2 (en) 2015-12-18 2022-08-25 Ignyta, Inc. Combinations for the treatment of cancer
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
FI3439662T3 (fi) 2016-04-04 2024-09-04 Loxo Oncology Inc (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
AU2017246547B2 (en) 2016-04-04 2023-02-23 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP3458456B1 (fr) 2016-05-18 2020-11-25 Loxo Oncology Inc. Préparation de (s)-n-(5-((r)-2-(2,5-difluorophényl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
KR102718538B1 (ko) 2017-07-19 2024-10-21 이그니타, 인코포레이티드 엔트렉티닙을 포함하는 약학적 조성물
CN111225662B (zh) 2017-10-17 2022-11-22 伊尼塔公司 药物组合物和剂型
IL276398B2 (en) 2018-01-31 2026-03-01 Deciphera Pharmaceuticals Llc Combination therapy for mastocytosis
CN118416236A (zh) 2018-01-31 2024-08-02 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
WO2020185812A1 (fr) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Formes à l'état solide de riprétinib
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
EP4013412B1 (fr) 2019-08-12 2026-01-28 Deciphera Pharmaceuticals, LLC Ripretinib pour le traitement de tumeurs stromales gastro-intestinales
CN110643672A (zh) * 2019-10-15 2020-01-03 西安交通大学 高表达TrkB作为新型靶点在抑制胰腺癌转移方面的医药用途
MX2022008103A (es) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
EP4084779B1 (fr) 2019-12-30 2024-10-09 Deciphera Pharmaceuticals, LLC Compositions de 1-(4-bromo-5-(1-éthyl-7-(méthylamino)-2-oxo-1,2-dihydro -1,6-naphthyridine-3-yl)-2-fluorophényl)-3-phényluree
WO2021178789A1 (fr) * 2020-03-06 2021-09-10 Deciphera Pharmaceuticals, Llc Procédés d'utilisation de rebastinib dans le traitement de différents troubles cancéreux
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
CN116254253B (zh) * 2022-11-11 2024-06-28 浙大宁波理工学院 一种通过dna合成改组组合突变获得的谷氨酸脱羧酶突变体及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002275068A (ja) * 2001-03-16 2002-09-25 Kyowa Hakko Kogyo Co Ltd アポトーシス誘導剤
CA2544074A1 (fr) * 2003-10-24 2005-05-06 Esbatech Ag Procede pour l'identification et/ou la validation d'inhibiteurs de tyrosine-kinases receptrices
WO2006111035A1 (fr) * 2005-04-21 2006-10-26 Oncalis Ag Methode d'identification de mutations potentiellement dangereuses du recepteur tyrosine kinase (rtk) et d'inhibiteurs ou de medicaments diriges contre les mutants de rtk
KR20080046161A (ko) * 2005-08-09 2008-05-26 요하네스 구텐베르크-유니버시타트 마인츠 비-소세포 폐암의 치료를 위한 스타우로스포린 유도체
SG177225A1 (en) * 2006-12-01 2012-01-30 Agency Science Tech & Res Cancer-related protein kinases
PT2176231T (pt) * 2007-07-20 2016-12-09 Nerviano Medical Sciences Srl Derivados de indazol substituídos activos como inibidores de quinases
JP5758289B2 (ja) * 2008-05-21 2015-08-05 サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、（セーエヌエルエス） ＮＴ−３：ＴｒｋＣ結合の阻害および神経芽腫などの癌の処置へのその適用
MY169791A (en) * 2008-10-22 2019-05-15 Array Biopharma Inc Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
US8383793B2 (en) * 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
MA34969B1 (fr) * 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
CN102924479A (zh) * 2011-08-09 2013-02-13 山东鲁北药业有限公司 一种星孢菌素类衍生物的半合成方法

Also Published As

Publication number Publication date
US20210322439A1 (en) 2021-10-21
AU2016270321B2 (en) 2020-09-10
CN107849113A (zh) 2018-03-27
US20180177792A1 (en) 2018-06-28
EP3303382A4 (fr) 2018-12-19
HK1252821A1 (zh) 2019-06-06
CA2987281A1 (fr) 2016-12-08
AU2016270321A2 (en) 2018-01-04
JP6929231B2 (ja) 2021-09-01
AU2016270321A1 (en) 2017-12-14
EP3303382A1 (fr) 2018-04-11
WO2016196141A1 (fr) 2016-12-08
JP2021156893A (ja) 2021-10-07
JP7219791B2 (ja) 2023-02-08
CN107849113B (zh) 2022-03-22
JP2018521973A (ja) 2018-08-09

Similar Documents

Publication Publication Date Title
MA43943A (fr) Compositions et procédés pour traiter des patients avec des cellules mutantes rtk
EP3503901A4 (fr) Procédés et compositions pour cellules de moelle épinière
EP3386484A4 (fr) Compositions et procédés permettant d'administrer des agents thérapeutiques
EP3472307A4 (fr) Procédés et compositions de potentialisation de thérapies de cellules souches
MA45408A (fr) Compositions et procédés pour la déplétion des cellules cd117+
EP2961828A4 (fr) Procédés et compositions pour mobiliser des cellules souches
IL257105A (en) Modified cells and methods of therapy
SI3194570T1 (sl) Postopki in sestavki za genomski inženiring s posredovanjem nukleaze in korekcijo krvotvornih matičnih celic
SI3215601T1 (sl) Postopki za transdukcijo in obdelavo celic
SI3212225T1 (sl) Postopki in sestavki za modificirane celice T
HUE053485T2 (hu) Készítmények és eljárások meibom-mirigy diszfunkció kezelésére
EP2947990A4 (fr) Compositions et procédés pour traiter des organismes nuisibles
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
IL246791A0 (en) Compositions and methods for treating eye diseases
EP3302532A4 (fr) Compositions et procédés en rapport avec des agents biologiques antistaphylococciques
EP3534911A4 (fr) Procédés et compositions pour la reprogrammation cellulaire
EP3503879A4 (fr) Compositions et procédés associés
EP3394272A4 (fr) Compositions et procédés permettant de cibler efficacement des transgènes
EP4012024C0 (fr) Procédés pour améliorer la thérapie cellulaire
EP3307284A4 (fr) Compositions et procédés pour l'enrichissement de cellules
PL3166911T3 (pl) Wprowadzanie czynników biologicznych do nawozów
EP3353287A4 (fr) Compositions et procédés pour produire des cellules dendritiques
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
EP3645020A4 (fr) Compositions et procédés pour la thérapie cellulaire adoptive
EP3390641A4 (fr) Compositions et procédés pour manipuler le développement des plantes